Related Experiment Videos
[Tumor markers in gynecology]
L C Fuith1, E Artner-Dworzak, G Daxenbichler
1Universitätsklinik für Frauenheilkunde, Innsbruck.
Wiener Klinische Wochenschrift
|July 14, 1989
Summary
Tumour markers like Beta HCG and alpha 1 fetoprotein are crucial for gynaecological cancer surveillance. Established markers and promising new ones like SCC and neopterin aid in diagnosis and prognosis.
Area of Science:
- Gynaecology
- Oncology
- Biochemistry
Context:
- The use of tumour markers in gynaecology is increasingly important.
- Established markers include Beta HCG, alpha 1 fetoprotein, CEA, TPA, and CA 125.
- Newer markers like SCC and neopterin show significant promise.
Purpose:
- To review the current landscape and emerging trends in gynaecological tumour marker utilization.
- To highlight the role of specific tumour markers in diagnosing and monitoring various gynaecological cancers.
- To discuss the prognostic value of certain markers in gynaecological oncology.
Summary:
- Beta HCG and alpha 1 fetoprotein are essential for postoperative surveillance of chorionic carcinoma and germ cell tumours, respectively.
- Established tumour markers such as CEA, TPA, and CA 125 are widely recognized.
- Promising results are emerging for SCC in cervical carcinoma and neopterin as a marker for cell-mediated immunity with good prognostic information.
Impact:
- Improved diagnostic accuracy and patient monitoring in gynaecological oncology.
- Enhanced prognostic assessment through the use of specific tumour markers.
- Potential for earlier detection and more effective treatment strategies for gynaecological cancers.